Data Sheet (Cat.No.T4344)

TargetMol

ALW-II-41-27

Chemical Properties



CAS No. : 1186206-79-0

Formula: C32H32F3N5O2S

Molecular Weight: 607.69

Storage: Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	ALW-II-41-27 (Eph receptor tyrosine kinase inhibitor), an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
Targets(IC50)	Ephrin Receptor
In vitro	ALW-II-41-27 inhibits Ba/F3 cells (EC50<500 nM) transformed with Tel fusions of Kit, EphA3, Fms, KDR, FLT1, FGR, Src, Bmx, Lyn, and Bcr-Abl, and shows cross-reactivity with Bcr-Abl. Additionally, ALW-II-41-27 inhibits b-Raf, CSF1R, DDR1, DDR2, EphA2, EphA8, EphB1, EphB2, Kit, EphB3, Frk, Lck, EphA5, p38α, p38β, PDGFRβ, PDGFRα, and Raf1.

Solubility Information

Solubility	DMSO: 120 mg/mL (197.47 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.29 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6456 mL	8.2279 mL	16.4558 mL
5 mM	0.3291 mL	1.6456 mL	3.2912 mL
10 mM	0.1646 mL	0.8228 mL	1.6456 mL
50 mM	0.0329 mL	0.1646 mL	0.3291 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Choi, et al. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters (2009), 19(15), 4467-4470.
Song W,etal.Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.Oncogene. 2017 Oct 5;36(40):5620-5630.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481